About Contact Us Careers
Sign In

Oral Immunostimulant Market Size & Share, by Type (Interleukins, Glucan, Lipopolysaccharides, Levamisole, Isoprinosine); Application (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5862
  • Published Date: May 09, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Oral Immunostimulant Market size is poised to reach USD 33.6 Billion by the end of 2036, growing at a CAGR of 7.5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the oral immunostimulant was USD 23 Billion, which is attributed to the rising cases of chronic diseases like cancer, and cardiovascular diseases which weaken the immune system.

According to a recent report, there were almost 17.8 million deaths in 2019 due to cardiovascular diseases worldwide. Furthermore, the role of oral immunostimulants is crucial in bolstering the immune system which leads to stimulating the market.

In addition, there is a growing demand for oral immunostimulants globally as patients seek comfortable treatment options over other forms of treatment. Oral Immunostimulant is a convenient option for patients as it can be taken in pill or liquid form. Moreover, oral immunostimulant reduces the possible infections and other complications among patients which further boosts the growth of the market.

Get more information on this report: Request Free Sample PDF

Oral Immunostimulant Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing awareness about oral immunostimulants - Pharmaceutical and healthcare organizations conduct campaigns to educate the public about the benefits of oral immunostimulants, their mechanisms, and their positive impact on overall health.

    Moreover, the creation and distribution of educational material including brochures, pamphlets, and digital content that explains the science behind oral immunostimulants and their role in supporting the immune system will boost the market.
  • Emergence of technological advancement - Technological advancement contributes to the formulation, delivery, and overall efficacy of oral immunostimulants. Additionally, rising healthcare spend also contributes to the market growth. According to a recent report, global spending on health reached USD 9.8 trillion or 10.3% of the global domestic product (GDP) in 2021. 

    The use of nanotechnology enables the creation of nanoparticles that improve the solubility of immunostimulants, facilitate better absorption, and enhance overall effectiveness. In addition, the integration of genetic engineering and recombinant DNA technology enables the production of oral immunostimulants with improved purity and consistency.
  • Aging population more susceptible to infections - As people age, their immune system naturally weakens. This weakening makes older adults more susceptible to infections, and diseases, thereby increasing the need for interventions that boost their immune responses which increase the demand for oral immunostimulants.

    Moreover, the aging population has more chronic conditions, in this case, immunostimulants can help in managing these conditions by reducing the risk of infections and complications. Immunostimulant improves the quality of life and potentially reduce healthcare costs. Furthermore, the aging population not only represents a growing segment of the demographic but also a group with specific healthcare needs that oral immunostimulants can address.

Challenges

  • Competition from alternative therapies - There is a rise in competition from alternative therapies such as injectable immunostimulants, traditional medicines, and dietary supplements in the oral immunostimulant market. Convincing healthcare professionals and consumers about the unique benefits of oral immunostimulants can be challenging.
  • The lack of complete understanding of immune system modulation can hinder the development of targeted oral immunostimulants.
  • Regulatory agencies have stringent requirements for approving healthcare products such as oral immunostimulants which hampers the market.

Oral Immunostimulant Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

 ~ 7.5%

Base Year Market Size (2023)

~ USD 23 Billion

Forecast Year Market Size (2036)

~ USD 33.6 Billion

Regional Scope
  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Oral Immunostimulant Segmentation

By Type (Interleukins, Glucan, Lipopolysaccharides, Levamisole, Isoprinosine)

In oral Immunostimulant market, interleukins segment is likely to dominate around 51% share by the end of 2036. The segment growth can be attributed to the factor that interleukins are involved in the modulation and responses of immune responses. Oral immunostimulants that leverage the specific interleukins can influence the immune system’s activity, helping to enhance the body’s defense mechanisms against infections or diseases.

In addition, the ongoing research into the roles of interleukins in immune functions fuels innovation in the oral immunostimulants market. Companies are exploring ways to harness the potential of interleukins for developing next-generation oral immunostimulant products that stimulate segment growth.

By Application (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)

In oral Immunostimulant market, hospital pharma segment is predicted to hold over 54% revenue share by the end of 2036. The segment growth can be attributed to the factor that hospitals play a crucial role in the treatment of acute illness and infectious diseases. According to a recent report, a total of 66 infectious diseases were reported in 2021.

Oral immunostimulants are often prescribed in these settings to support patient immune responses during their stay in hospitals, aiding in faster recovery

Our in-depth analysis of the global market includes the following segments:

          By Type
  • Interleukins
  • Glucan
  • Lipopolysaccharides
  • Levamisole
  • Isoprinosine

          By Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores,
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Oral Immunostimulant Treatment Industry - Regional Synopsis

North American Market Forecast

By the end of 2036, North America region is projected to account for more than 44% oral Immunostimulant market share. The regional growth is attributed to the factor that well-established healthcare infrastructure and a high prevalence of chronic diseases.

In addition, the COVID-19 pandemic has highlighted the importance of immune health, leading to a surge in interest and investment in immunostimulant therapies. According to a recent report, there were at least 1,064,000 reported deaths caused by a novel coronavirus in North America in 2022. As a result, oral immunostimulants have gained attention as a potential tool for enhancing the body’s natural defenses against infections, including respiratory illnesses like COVID-19 which stimulate the market in the region.

European Market Analysis

By 2036, Europe region in oral Immunostimulant market is set to capture over 30% revenue share. The market’s expansion can be attributed to Europe’s commitment to healthcare innovation and huge investment in healthcare research created a favorable environment for the oral immunostimulant market.

In addition, the integration of digital health tools like mobile health applications helps in patient monitoring and provides real-time data. This digital integration improves overall patient management and contributes to the effectiveness of oral immunostimulant therapies. Moreover, healthcare innovation in the region acts as a catalyst for the growth of the oral immunostimulant market by pushing the boundaries of scientific knowledge improving treatment outcomes, and addressing immune-related disorders and infectious diseases.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Oral Immunostimulant Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Step-Pharma
    • Abbott
    • Biogen
    • Novartis AG
    • Amgen
    • Merck & Co.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company

In the News

  •  Abbott announced that Abbott HeartMates Programs which is a new initiative that will kick off with professional football player Damar Hamlin as its first ambassador. Moreover, Abbott has invited people who are committed to inspiring others through their heart-healthy stories to join Hamlin in the HeathMates team. The team is comprised of people who are affected by health conditions including cardiovascular patients, caregivers, family, and friends. The team will collaborate directly with Abbott and Hamlin as a program ambassador and promote HeartMates community-building tenets to those impacted by heart conditions.
  • Step Pharma announced that pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, were presented at the 64th American Society for Hematology Annual Meeting held from 10-13 December 2022 in New Orleans virtually. Moreover, the data presented by Step Pharma collaborators demonstrates the potential of STP938, a highly selective CTPS1 inhibitor, as a therapeutic for the treatment of mantle cell lymphoma and multiple myeloma both as a single agent and in combination with other targeted inhibitors. Moreover, single agent STP938 also showed activity in preclinical models of multiple myeloma and demonstrated strong synergy when combined with an inhibitor of DNA in the damage response pathway.

Author Credits:  Radhika Pawar


  • Report ID: 5862
  • Published Date: May 09, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing awareness of Oral immunostimulants, the emergence of technological advancement, aging population being more susceptible to infections are the major factors driving the growth of the oral immunostimulant market.

The market size of oral immunostimulants is anticipated to attain a CAGR of 7.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Step Pharma, Biogen, Abbott, Amgen, Novartis AG, Merck & Co., and others.

The type segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Oral Immunostimulant Market Report Scope

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample